MedTrace Logo

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

NCT03844945 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan

Conditions

Interventions

DRUG

Netarsudil Ophthalmic Solution 0.01%

Topical sterile ophthalmic solution

DRUG

Netarsudil Ophthalmic Solution 0.02%

Topical sterile ophthalmic solution

DRUG

Netarsudil Ophthalmic Solution 0.04%

Topical sterile ophthalmic solution

OTHER

Netarsudil Ophthalmic Solution Placebo

Topical sterile ophthalmic solution

Sponsors & Collaborators

  • Aerie Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Kenji Aso, M.D., Ph.D. · Aerie Pharmaceuticals Ireland Ltd. (Japan Branch)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-19
Primary Completion
2019-09-19
Completion
2019-09-19
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03844945 on ClinicalTrials.gov